

论著

阿托伐他汀抑制RhoA/Rho激酶活性逆转低氧性肺动脉高压大鼠肺动脉高压和肺血管重构

代丽, 吴尚洁

中南大学湘雅二医院呼吸内科, 长沙 410011

摘要:

目的: 探讨阿托伐他汀是否通过抑制肺动脉RhoA/Rho激酶通路的激活而逆转低氧所致的大鼠肺动脉高压及肺血管重构。方法: 32只成年雄性Westar大鼠随机分成4组: A组为正常对照组; B, C, D组建立常压低氧性肺动脉高压大鼠模型, 自低氧干预第1天起C组每日给予1 mg/mL阿托伐他汀溶液10 mg/kg灌胃, D组以生理盐水10 mL/kg灌胃。模型建成时右心导管测定肺动脉平均压(mPAP); 肺组织病理切片对肺小血管周围炎性细胞浸润和肺血管结构改变进行评分, 采用病例图像分析系统测定肺小动脉管壁厚度占外径的百分比(WT%) 和管壁面积占血管总面积的百分比(WA%), 评价肺血管重构的严重程度; Western印迹检测肺动脉组织蛋白中RhoA的表达, Rho激酶的调节亚单位MYPT 1磷酸化水平。结果: 低氧干预B组大鼠mPAP, 右室肥大指数 [RV/(LV+S)], WT%, WA% 分别为(29.6±1.1) mmHg, (39.0±0.7)%, (35.6±2.4)%, (56.5±5.1)%, 较正常对照组 [(16.8±0.7) mmHg, (29.4±0.5)%, (22.3±1.2)%, (36.6±2.3)%] 增高, 差异均有统计学意义 (P<0.05); 经阿托伐他汀干预C组大鼠mPAP, RV/(LV+S), WT%, WA% 分别为(25.3±3.2) mmHg, (36.3±2.1)%, (29.2±3.2)%, (48.1±2.7)%, 较正常对照组A组高 (P<0.05), 同时较低氧干预B组低 (P<0.05); 生理盐水对照D组上述指标均与低氧干预C组无明显差别。Western 印迹结果显示: 在B组大鼠肺动脉组织中RhoA, 磷酸化MYPT 1表达明显较A组大鼠上调, C组大鼠则较B组大鼠有明显减低。结论: 阿托伐他汀能显著降低低氧性肺动脉高压大鼠的mPAP, 改善肺血管的重构, 其作用机制可能与阿托伐他汀抑制肺动脉中RhoA/Rho激酶活性有关。

关键词: 低氧性肺动脉高压; 阿托伐他汀; RhoA/Rho激酶

扩展功能

本文信息

- Supporting info
- PDF(1479KB)
- [HTML全文]
- 参考文献[PDF]
- 参考文献

服务与反馈

- 把本文推荐给朋友
- 加入我的书架
- 加入引用管理器
- 引用本文
- Email Alert
- 文章反馈
- 浏览反馈信息

本文关键词相关文章

- 低氧性肺动脉高压; 阿托伐他汀; RhoA/Rho激酶

本文作者相关文章

PubMed

Atorvastatin attenuates hypoxic pulmonary hypertension in rats by inhibiting RhoA/Rho kinase pathway

DAI Li, WU Shangjie

Department of Respiratory, Second Xiangya Hospital, Central South University, Changsha 410011, China

Abstract:

Objective To investigate whether atorvastatin treatment can improve the symptoms of hypoxia induced pulmonary hypertension in rats by inhibiting RhoA/Rho kinase pathway. Methods A total of 32 Westar rats was divided into 4 groups: normoxic controls (Group A), hypoxic controls (Group B), hypoxia plus atorvastatin [10 mg/ (kg · d)] group (Group C), and hypoxia plus the vehicle of atorvastatin (Group D). Rats for hypoxia treatment were maintained under the condition of 10% FiO₂ 6 h/d for 4 weeks. At the end of 4 weeks, rats were anesthetized and the mean pulmonary arterial pressure (mPAP) was measured by right heart catheterization. The ratios of arteriole wall thickness to vascular external diameter (WT%), and vascular area to total vascular area (WA%) were measured by a computerized image analyzer. RhoA and phos MYPT 1 expression in the pulmonary artery were determined by Western blot. Results Comparing with Group A, the mPAP [(29.6±1.1) mmHg vs (16.8±0.7) mmHg], RV/(LV+S) [(39.0±0.7) % vs (29.4±0.5) %], WT% [(35.6±2.4)% vs (22.3±1.2)%] and WA% [(56.5±5.1)% vs (36.6±2.3)%] in Group B were all significantly increased (P<0.05). Comparing with Group B, the mPAP [(25.3±3.2) mmHg], RV/(LV+S) [(36.3±2.1)%], WT% [(29.2±3.2)%] and WA% [(48.1±2.7)%] in Group C were significantly decreased. The vehicle of atorvastatin had no such effect. The expression of RhoA and phos MYPT 1 in the pulmonary artery was increased in Group B, but it was decreased in Group C. Conclusion RhoA/Rho kinase pathway plays an important role in the development of hypoxic pulmonary hypertension. Atorvastatin can improve the symptoms of hypoxic pulmonary hypertension by inhibiting RhoA/Rho kinase activity.

Keywords: hypoxic pulmonary hypertension; atorvastatin; RhoA/Rho kinase

收稿日期 2010-04-06 修回日期 网络版发布日期

DOI: 10.3969/j.issn.1672-7347.2011.

基金项目:

通讯作者: 吴尚洁

作者简介: 代丽, 硕士, 医师, 主要从事呼吸系统疾病防治研究。

作者Email: wushangjie@medmail.com.cn

参考文献:

- [1] Cool C D, Groshong S D, Oakey J, et al. Pulmonary hypertension: cellular and molecular mechanisms [J]. *Chest*, 2005, 128(6 Suppl):565S-571S.
- [2] Badejo A M Jr, Dhaliwal J S, Casey D B, et al. Analysis of pulmonary vasodilator responses to the Rho kinase inhibitor fasudil in the anesthetized rat [J]. *Am J Physiol Lung Cell Mol Physiol*, 2008, 295(5):L828-L836.
- [3] Rikitake Y, Liao J K. Rho GTPases, statins, and nitric oxide [J]. *Circ Res*, 2005, 97(12):1232-1235.
- [4] Oka M, Homma N, Taraseviciene-Stewart L, et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats [J]. *Circ Res*, 2007, 100(6):923-929.
- [5] 薛全福, 胡长贵. 常压缺氧性大鼠肺动脉高压模型的建立 [J]. *中华结核和呼吸杂志*, 1989, 12(6):350-352.
- XUE Quanfu, HU Changgui. A model of rat pulmonary hypertension established by normobaric hypoxia [J]. *Chinese Journal of Tuberculosis and Respiratory Diseases*, 1989, 12(6):350-352.
- [6] Guerard P, Rakotoniaina Z, Goirand F, et al. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS [J]. *Naunyn-Schmiedeberg's Arch Pharmacol*, 2006, 373(6):401-414.
- [7] Stenmark K R, McMurtry I F. Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: A time for reappraisal? [J]. *Circ Res*, 2005, 97(2):95-98.
- [8] Morty R E, Nejman B, Kwapiszewska G, et al. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension arteriosclerosis [J]. *Arterioscler Thromb Vasc Biol*, 2007, 27(5):1072-1078.
- [9] Knock G A, Snetkov V A, Shaifita Y, et al. Superoxide constricts rat pulmonary arteries via Rho kinase-mediated Ca²⁺ sensitization [J]. *Free Radic Biol Med*, 2009, 46(5):633-642.
- [10] Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a Rho kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats [J]. *Circ Res*, 2004, 94(3):385-393.
- [11] Alegret M, Silvestre J S. Pleiotropic effects of statins and related pharmacological experimental approaches [J]. *Methods Find Exp Clin Pharmacol*, 2006, 28(9):627-656.
- [12] Amaud C, Burger F, Stefens S, et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct anti-inflammatory effects of statins [J]. *Arterioscler Thromb Vasc Biol*, 2005, 25(6):1231-1236.
- [13] Wu S, Duan S, Zhao S, et al. Atorvastatin reduces lipopolysaccharide-induced expression of cyclooxygenase-2 in human pulmonary epithelial cells [J]. *Respir Res*, 2005, 6:27.
- [14] 吴尚洁, 赵水平. 阿托伐他汀对脂多糖诱导的人肺上皮细胞分泌PGE₂和IL-6的影响 [J]. *中南大学学报: 医学版*, 2004, 29(2):192-194.
- WU Shangjie, ZHAO Shuiping. Effects of atorvastatin on LPS-induced PGE₂ and IL-6 secretions in human pulmonary epithelial cells [J]. *Journal of Central South University. Medical Science*, 2004, 29(2):192-194.
- [15] 吴尚洁, 邢西迁, 甘焯, 等. 阿托伐他汀对脂多糖诱导下人肺上皮细胞C反应蛋白表达的影响 [J]. *中南大学学报: 医学版*, 2009, 34(2):104-108.
- WU Shangjie, XING Xiqian, GAN Ye, et al. Effect of atorvastatin on lipopolysaccharide-induced expression of C-reactive protein in human pulmonary epithelial cells [J]. *Journal of Central South University. Medical Science*, 2009, 34(2):104-108.
- [16] Duan S, Zhang Y, Wu S J, et al. Atorvastatin attenuates inflammatory infiltration and vascular remodeling in lung of hypercholesterolemia rabbits [J]. *Exp Lung Res*, 2010, 36(10):573-592.

本刊中的类似文章